# Mifepristone Mail Access Restored by Supreme Court
The U.S. Supreme Court restored access to mifepristone by mail, allowing patients to continue receiving the medication through the postal service. This decision reverses restrictions that had threatened to limit how women access medication abortion.
Mifepristone is the first pill in a two-drug combination used for medication abortion up to 10 weeks of pregnancy. The FDA approved it for mail delivery in 2023, removing the requirement that patients pick it up in person at clinics or hospitals. This change expanded access for people in rural areas and states with abortion restrictions.
The court's action matters because it protects a proven safe option. Medication abortion accounts for more than half of all abortions in the United States. Studies show mail delivery doesn't increase serious complications. The American College of Obstetricians and Gynecologists supports mail access as safe and effective.
For families weighing reproductive options, this ruling preserves one path forward. Women can now consult with providers remotely and receive medication at home, rather than traveling to clinics. This reduces logistical barriers, costs, and time away from work or caregiving.
The decision also reflects ongoing legal battles over abortion access. Multiple states have attempted to restrict or ban mifepristone entirely, while others protect it. Patients need to check their state's laws, as availability still varies by location. Some states prohibit abortion altogether, while others allow it and support mail delivery.
Telehealth providers like Hey Jane, Nurx, and Blinkhealth offer consultations for medication abortion in states where it's legal. Patients should verify their state's regulations before seeking care.
This ruling gives families more control over reproductive decisions during uncertain times. Access to medication abortion by mail removes geographic barriers and offers privacy and convenience that clinic visits cannot match.